LONDON: Hikma Pharmaceuticals, the multinational pharmaceutical company, and Gedeon Richter PLC announced the signing of an exclusive license agreement to commercialise cariprazine, a novel antipsychotic, in certain Middle East and North African (MENA) markets. Under the terms of the agreement, Richter will be responsible for product supply and Hikma will proceed with the registration and…